Gene signatures of c-Rel+ in the overall DLBCL cohort (false discovery rate < .10), and gene signatures of REL amplification identified in the overall (false discovery rate < .05, fold change >2) or GCB-DLBCL cohort (false discovery rate < .05). This evidence concerns the gene REL and diffuse large B-cell lymphoma.